CytomX Therapeutics, Inc.

Submit Your Information

Company Name	CytomX Therapeutics, Inc.
Stock Symbol	CTMX
Class Period	May 17, 2018 to May 13, 2020
Lead Plaintiff Motion Deadline	July 20, 2020

On May 13, 2020, the Company made available abstracts for the Company’s clinical presentations for CX-072 and CX-2009. Results from the PROCLAIM-CX-072 clinical program revealed a response rate of 8.8%, compared to a response rate of 18.5% in patients receiving the combination of CX-072 and ipilimumab. Meanwhile, results from the PROCLAIM-CX-2009 clinical program showed “evidence” of clinical activity at doses at least 4 mg/kg 3x/week, but also suggested a significantly higher rate of serious or greater treatment-related toxicity to the eyes at dose equivalents at least 8 mg/kg 3x/week.

On this news, the Company’s share price fell $5.21 per share, or over 36%, to close at $9.23 per share on May 14, 2020, thereby injuring investors.

Submit Your Information

If you suffered a loss on your CytomX Therapeutics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before May 17, 2018?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments